(Q50235068)

English

The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.

scientific article published on 8 February 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 February 2018

http://europepmc.org/abstract/MED/26856695

The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. (English)

1 reference

Europe PubMed Central

28 February 2018

http://europepmc.org/abstract/MED/26856695

0 references

chronic schizophrenia

1 reference

based on heuristic

inferred from title

author name string

Negar Iranpour

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Mehdi Farokhnia

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Amirhossein Goguol

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Habibeh Yekehtaz

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Mohammad-Reza Khodaie-Ardakani

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Bahman Salehi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Atefeh Zeionoddini

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Payam Mohammadinejad

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Arefeh Zeinoddini

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Shahin Akhondzadeh

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

8 February 2016

1 reference

Europe PubMed Central

28 February 2018

http://europepmc.org/abstract/MED/26856695

Human Psychopharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

103-112

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Inflammation and schizophrenia: alterations in cytokine levels and perturbation in antioxidative defense systems.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

The peroxisome proliferator-activated receptor γ (PPARγ) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

The NF-kappaB regulatory network

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Persistent negative symptoms in schizophrenia: an overview

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Manual for the Extrapyramidal Symptom Rating Scale (ESRS).

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Cross-talk between nuclear receptors and nuclear factor kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Agonists for Neurological Disease

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Schizophrenia as a membrane lipid disorder which is expressed throughout the body

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Negative symptoms in schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Inflammation in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Stress-induced neuroinflammation: mechanisms and new pharmacological targets.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Schizophrenia and the immune system: pathophysiology, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

21 January 2018

Beschleunigter Abbau von Membranphospholipiden bei der Schizophrenie - Implikationen für die Hypofrontalitätshypothese

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2517

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HUP.2517

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26856695%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50235068&oldid=1510043954"